AVDL
Price
$21.36
Change
+$0.01 (+0.05%)
Updated
Dec 3 closing price
Capitalization
2.09B
95 days until earnings call
Intraday BUY SELL Signals
RDY
Price
$14.13
Change
+$0.03 (+0.21%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
11.74B
50 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AVDL vs RDY

Header iconAVDL vs RDY Comparison
Open Charts AVDL vs RDYBanner chart's image
Avadel Pharmaceuticals
Price$21.36
Change+$0.01 (+0.05%)
Volume$2.17M
Capitalization2.09B
Dr. Reddy's Laboratories
Price$14.13
Change+$0.03 (+0.21%)
Volume$10.99K
Capitalization11.74B
AVDL vs RDY Comparison Chart in %
View a ticker or compare two or three
VS
AVDL vs. RDY commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVDL is a Hold and RDY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (AVDL: $21.36 vs. RDY: $14.10)
Brand notoriety: AVDL: Notable vs. RDY: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AVDL: 43% vs. RDY: 26%
Market capitalization -- AVDL: $2.1B vs. RDY: $11.74B
AVDL [@Pharmaceuticals: Generic] is valued at $2.1B. RDY’s [@Pharmaceuticals: Generic] market capitalization is $11.74B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVDL’s FA Score shows that 0 FA rating(s) are green whileRDY’s FA Score has 0 green FA rating(s).

  • AVDL’s FA Score: 0 green, 5 red.
  • RDY’s FA Score: 0 green, 5 red.
According to our system of comparison, AVDL is a better buy in the long-term than RDY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVDL’s TA Score shows that 2 TA indicator(s) are bullish while RDY’s TA Score has 5 bullish TA indicator(s).

  • AVDL’s TA Score: 2 bullish, 5 bearish.
  • RDY’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RDY is a better buy in the short-term than AVDL.

Price Growth

AVDL (@Pharmaceuticals: Generic) experienced а -6.85% price change this week, while RDY (@Pharmaceuticals: Generic) price change was +1.59% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.67%. For the same industry, the average monthly price growth was +0.42%, and the average quarterly price growth was +25.91%.

Reported Earning Dates

AVDL is expected to report earnings on Mar 09, 2026.

RDY is expected to report earnings on Jan 23, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+3.67% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDY($11.7B) has a higher market cap than AVDL($2.09B). AVDL YTD gains are higher at: 103.235 vs. RDY (-10.144). RDY has higher annual earnings (EBITDA): 98.1B vs. AVDL (7.87M). RDY has more cash in the bank: 66.7B vs. AVDL (81.5M). AVDL has less debt than RDY: AVDL (2.73M) vs RDY (48.6B). RDY has higher revenues than AVDL: RDY (334B) vs AVDL (221M).
AVDLRDYAVDL / RDY
Capitalization2.09B11.7B18%
EBITDA7.87M98.1B0%
Gain YTD103.235-10.144-1,018%
P/E RatioN/A17.72-
Revenue221M334B0%
Total Cash81.5M66.7B0%
Total Debt2.73M48.6B0%
FUNDAMENTALS RATINGS
AVDL vs RDY: Fundamental Ratings
AVDL
RDY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
3665
SMR RATING
1..100
9252
PRICE GROWTH RATING
1..100
3655
P/E GROWTH RATING
1..100
3743
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RDY's Valuation (78) in the Pharmaceuticals Generic industry is in the same range as AVDL (83) in the Medical Specialties industry. This means that RDY’s stock grew similarly to AVDL’s over the last 12 months.

AVDL's Profit vs Risk Rating (36) in the Medical Specialties industry is in the same range as RDY (65) in the Pharmaceuticals Generic industry. This means that AVDL’s stock grew similarly to RDY’s over the last 12 months.

RDY's SMR Rating (52) in the Pharmaceuticals Generic industry is somewhat better than the same rating for AVDL (92) in the Medical Specialties industry. This means that RDY’s stock grew somewhat faster than AVDL’s over the last 12 months.

AVDL's Price Growth Rating (36) in the Medical Specialties industry is in the same range as RDY (55) in the Pharmaceuticals Generic industry. This means that AVDL’s stock grew similarly to RDY’s over the last 12 months.

AVDL's P/E Growth Rating (37) in the Medical Specialties industry is in the same range as RDY (43) in the Pharmaceuticals Generic industry. This means that AVDL’s stock grew similarly to RDY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVDLRDY
RSI
ODDS (%)
Bearish Trend 6 days ago
86%
Bullish Trend 6 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
83%
Bearish Trend 6 days ago
55%
Momentum
ODDS (%)
N/A
Bullish Trend 6 days ago
50%
MACD
ODDS (%)
Bearish Trend 6 days ago
71%
Bullish Trend 6 days ago
49%
TrendWeek
ODDS (%)
Bearish Trend 6 days ago
80%
Bullish Trend 6 days ago
49%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
85%
Bearish Trend 6 days ago
49%
Advances
ODDS (%)
Bullish Trend 20 days ago
84%
Bullish Trend 6 days ago
50%
Declines
ODDS (%)
Bearish Trend 16 days ago
82%
N/A
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
80%
Bullish Trend 6 days ago
48%
Aroon
ODDS (%)
Bullish Trend 6 days ago
84%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
AVDL
Daily Signal:
Gain/Loss:
RDY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TWIEX14.00N/A
N/A
American Century International Gr Inv
PAGEX17.48N/A
N/A
T. Rowe Price Global Real Estate Adv
PDSIX51.47N/A
N/A
PGIM Quant Solutions Large-Cap Index I
WINDX38.02N/A
N/A
FT Wilshire 5000 Index Instl
TWCGX67.13N/A
N/A
American Century Growth Inv

AVDL and

Correlation & Price change

A.I.dvisor tells us that AVDL and RMTI have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AVDL and RMTI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVDL
1D Price
Change %
AVDL100%
-0.28%
RMTI - AVDL
33%
Poorly correlated
+1.08%
ELAN - AVDL
29%
Poorly correlated
-0.53%
COLL - AVDL
27%
Poorly correlated
+1.37%
VTRS - AVDL
27%
Poorly correlated
+0.09%
RDY - AVDL
26%
Poorly correlated
+1.15%
More

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and COLL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and COLL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
+1.15%
COLL - RDY
29%
Poorly correlated
+1.37%
VTRS - RDY
28%
Poorly correlated
+0.09%
TAK - RDY
28%
Poorly correlated
-1.04%
HROW - RDY
27%
Poorly correlated
+0.98%
KMDA - RDY
26%
Poorly correlated
+3.05%
More